Market Outlook

By 2035, the U.S. Single-Use Point-of-Care Testing Devices Market is expected to reach approximately USD 31.09 billion, expanding at a CAGR of 11.34% during the forecast period 2026–2035. The market is estimated at USD 10.62 billion in 2025. Historical analysis covers 2021–2024, and all market values in this report are expressed in USD billions.

The market represents one of the most strategically important recurring-revenue areas within U.S. decentralized diagnostics. Unlike conventional central-laboratory testing, single-use point-of-care devices generate value each time a test is performed. Test strips, lateral-flow cards, disposable cassettes, molecular cartridges, single-use microfluidic chips, biosensors and integrated specimen-collection devices are consumed at the site of care and replaced for every patient or testing event. This creates a business model driven by installed analyzer base, test frequency, disease incidence, seasonal infection patterns, patient monitoring intensity and expansion of testing into non-laboratory environments.

The historical market experienced an unusual demand pattern. Revenue is estimated at approximately USD 8.94 billion in 2021 and USD 9.82 billion in 2022, supported by extraordinary consumption of rapid SARS-CoV-2 tests across hospitals, pharmacies, workplaces, schools and homes. As pandemic-specific testing volumes normalized, the market contracted to approximately USD 9.12 billion in 2023. Growth resumed in 2024, taking the market to approximately USD 9.67 billion, before reaching USD 10.62 billion in 2025. The recovery reflects the transition from pandemic-driven single-analyte testing toward a broader, more durable decentralized diagnostic model built around multiplex respiratory panels, glucose testing, coagulation monitoring, cardiac biomarkers, pregnancy and fertility testing, urinalysis, blood chemistry and rapid molecular diagnostics.

The market is expected to reach approximately USD 11.82 billion in 2026, USD 18.17 billion by 2030 and USD 31.09 billion by 2035. Growth is therefore not dependent on another pandemic-scale event. The more important structural drivers are expansion of CLIA-waived testing, chronic disease prevalence, retail healthcare, urgent-care capacity, home diagnostics, rapid molecular platforms, microfluidic technology and demand for faster clinical decisions.

A major commercial advantage of single-use POC devices is their alignment with U.S. healthcare workflow economics. A hospital, urgent-care clinic or physician office may purchase an analyzer only once every several years, but every patient tested requires another cartridge, cassette or strip. Manufacturers that establish a large instrument footprint can therefore generate recurring consumables revenue while making switching more difficult for healthcare providers. Increasingly, the competitive battle is not centered on the reader itself; it is centered on the number, clinical relevance, reimbursement attractiveness and utilization frequency of assays that can be run through the platform.

 

Introduction

According to the U.S. Single-Use Point-of-Care Testing Devices Market Report, decentralized testing is becoming an increasingly important layer between conventional laboratory diagnostics and consumer-directed healthcare. Point-of-care testing allows clinicians to generate actionable information during the patient encounter rather than waiting for specimen transportation, centralized processing and result reporting. In emergency departments, urgent-care centers, physician offices, pharmacies and home settings, that time advantage can alter treatment decisions, patient disposition, antimicrobial prescribing and follow-up requirements.

For the purposes of this report, single-use point-of-care testing devices are defined as disposable diagnostic components intended for one patient, one specimen or one testing cycle. The category includes test strips and dipsticks, lateral-flow test cards, disposable reagent cassettes, molecular cartridges, microfluidic testing chips, single-use electrochemical sensors and integrated specimen collection-and-testing products. Reusable readers, handheld analyzers and benchtop POC instruments are treated primarily as enabling platforms and are not included in market revenue unless supplied as inseparable components of a disposable testing configuration.

The underlying U.S. testing infrastructure is substantial. More than 900,000 staffed hospital beds and over 35 million annual hospital admissions create a large institutional base for near-patient testing. Outside hospitals, the addressable network is expanding even faster. The country now has more than 15,000 urgent-care centers collectively treating well above 100 million patients annually, while community pharmacies, physician practices, ambulatory clinics, employer health programs and home-care channels increasingly function as diagnostic access points.

Regulatory structure also supports this decentralization. Waived testing represents the dominant certificate category within the U.S. CLIA laboratory framework. The importance of this is commercial as much as regulatory: simple, low-complexity tests can be deployed across a much broader universe of sites than conventional moderate- and high-complexity laboratory assays. This significantly expands the obtainable market for cartridges, cassettes and test strips designed around simplified workflows.

Single-use POC diagnostics also address a growing clinical requirement for immediate information. The U.S. has approximately 40 million people living with diagnosed or undiagnosed diabetes. More than 35 million adults are estimated to have chronic kidney disease. Respiratory infections generate recurrent seasonal demand, while cardiovascular disease, anticoagulation management, pregnancy testing, sexually transmitted infection screening and acute-care chemistry create additional high-frequency applications.

From 2026 through 2035, the strategic transition will be from individual rapid tests toward connected decentralized diagnostic ecosystems. Winning manufacturers will increasingly combine disposable assays with compact analyzers, digital interpretation, electronic health record connectivity, quality-control tools, remote fleet management and clinical decision support. For buyers, the critical metric will not simply be test price. It will be the total economic impact of obtaining a reliable result during the patient encounter.

 

Key Market Drivers: What’s Fueling the U.S. Single-Use Point-of-Care Testing Devices Market Boom?

One of the strongest drivers is the continued migration of diagnostic activity away from traditional centralized laboratories. U.S. healthcare is becoming more distributed across urgent-care centers, outpatient clinics, retail pharmacies, ambulatory facilities and homes. These environments require tests that are simple to store, easy to perform, fast to interpret and compatible with limited laboratory staffing. Single-use formats naturally fit this operating model because reagents can be premeasured and sealed within a cartridge, strip or cassette, minimizing preparation requirements and reducing contamination risk.

CLIA-waived testing is therefore a major commercial enabler. Waived tests are designed to be simple and carry a low risk of erroneous results when performed according to instructions. Their accessibility permits diagnostic manufacturers to address a far larger network of healthcare locations than would be available to complex laboratory platforms. For manufacturers, obtaining waiver status for strategically valuable assays can materially increase the addressable installed base and improve cartridge pull-through.

The second major driver is respiratory disease testing. COVID-19 permanently changed U.S. expectations regarding rapid diagnostics even as COVID-specific test demand normalized. Patients, clinicians, pharmacies and employers became accustomed to receiving infectious-disease results within minutes. The next commercial cycle is increasingly centered on multiplex testing that differentiates influenza A, influenza B, SARS-CoV-2 and, in certain platforms, RSV from a single patient encounter. This transition increases clinical utility compared with standalone COVID testing and supports a more sustainable seasonal demand pattern.

Rapid molecular diagnostics are especially important in this transition. Traditional antigen tests retain major advantages in price, simplicity and throughput, but molecular point-of-care tests provide substantially higher sensitivity in many applications and can deliver actionable results during the clinical visit. Disposable molecular cartridges are attractive commercially because they combine high assay value with recurring utilization, particularly in urgent care, physician offices and emergency settings.

A third growth engine is chronic disease testing. Diabetes remains one of the largest recurring testing opportunities in U.S. diagnostics. Although continuous glucose monitoring is changing diabetes management, blood glucose test strips remain relevant across hospitals, long-term care, acute care, selected home users and clinical confirmation workflows. Beyond glucose, point-of-care HbA1c, lipid testing, creatinine, kidney function assessment and other metabolic tests are expanding the role of decentralized testing in chronic disease screening and monitoring.

A fourth driver is healthcare labor economics. U.S. provider organizations face continuing pressure related to nursing capacity, laboratory staffing, turnaround times and patient throughput. A diagnostic product that removes manual pipetting, reagent preparation, calibration steps or specimen transport can create value beyond its acquisition price. In emergency and urgent-care workflows, saving 20–60 minutes on diagnostic turnaround can affect room utilization, clinician productivity and patient disposition. Procurement teams are therefore increasingly evaluating single-use tests according to labor minutes saved, avoided send-out testing, reduced patient callbacks and influence on treatment decisions.

A fifth driver is the growth of consumer and home testing. The rapid adoption of home COVID-19 testing demonstrated that U.S. consumers can successfully perform a large volume of diagnostics without direct laboratory supervision when products are designed for intuitive use. The FDA has since continued developing the regulatory foundation for home and over-the-counter diagnostics. Respiratory testing, pregnancy, fertility, glucose, cholesterol and selected infectious-disease applications increasingly demonstrate that the home can function as a legitimate testing site.

Retail pharmacy healthcare further reinforces this trend. U.S. pharmacy chains collectively operate tens of thousands of locations, giving the channel significant geographic reach. As pharmacies expand clinical services, testing programs can become a gateway to treatment, vaccination, referral or medication management. Single-use POC tests are particularly compatible with pharmacy economics because they require limited laboratory infrastructure and can be integrated into short patient encounters.

The sixth driver is the recurring-consumables economics of POC platforms. Once a healthcare system standardizes around a particular reader or analyzer, recurring cartridge purchases can become significant. This rewards companies that build broad assay menus. A platform capable of respiratory disease, coagulation, cardiometabolic and other tests can create substantially more customer lifetime value than a single-purpose instrument. Health systems may also prefer fewer analyzer platforms because consolidation reduces training, service contracts, inventory complexity and connectivity work.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. single-use POC testing market is moving toward higher information density per disposable device. The earlier generation of rapid testing was dominated by one strip or cassette generating one qualitative result. Emerging platforms increasingly extract several clinically relevant results from a single specimen and a single cartridge.

Multiplex respiratory diagnostics are one of the clearest examples. Differentiating influenza, COVID-19 and RSV can influence antiviral use, isolation decisions and patient counseling. Manufacturers are therefore competing to increase the number of targets without increasing workflow complexity. The economic value of these cartridges is not simply faster testing; it comes from reducing diagnostic uncertainty during the encounter.

Microfluidics is another major innovation area. Miniaturized channels can control specimen movement, reagent mixing and reaction timing within a disposable cartridge or chip. This allows sophisticated chemistry or immunoassay workflows to be shifted from laboratory instruments into compact near-patient platforms. Microfluidics also supports smaller specimen volumes, which is particularly valuable in pediatrics, critical care and finger-stick testing.

Rapid molecular testing is becoming increasingly competitive. Disposable nucleic-acid amplification cartridges can integrate extraction, amplification and detection while requiring minimal operator intervention. As assay times decline and multiplexing improves, rapid molecular platforms are moving into workflows that previously depended on antigen testing or laboratory PCR.

Digital interpretation is improving lateral-flow testing as well. Visually interpreted tests are inexpensive but can be vulnerable to reader subjectivity around faint test lines. Optical readers, smartphone-assisted interpretation and embedded digital systems can standardize result interpretation while generating electronic records. This is important for enterprise customers that need testing data to enter patient records, quality systems and public-health reporting infrastructure.

Specimen collection is also being redesigned. Manufacturers are combining swabs, buffers, transfer mechanisms and test devices into fewer user steps. In home testing, this reduces error risk. In professional settings, it reduces training burden and speeds throughput. The future single-use device will increasingly function as both specimen-handling system and analytical cartridge rather than simply a reagent container.

Sustainability is emerging as a procurement consideration because decentralized diagnostics generate substantial plastic, foil and biological waste. Large health systems are increasingly examining packaging volume, transport efficiency, hazardous-waste requirements and disposal. Manufacturers capable of reducing material intensity without compromising sterility, stability or performance could gain an advantage in enterprise contracting.

 

Segmentation Insights

The U.S. Single-Use Point-of-Care Testing Devices Market is segmented on the basis of product format, application, sample type, end-use setting and technology.

 

By Product Format

Test Strips and Dipsticks

Test strips and dipsticks represent the largest high-volume format, accounting for an estimated USD 3.35 billion in 2025. Blood glucose strips remain the principal contributor, complemented by urinalysis strips, ketone testing and other chemistry applications. Their commercial strength comes from low per-test cost, ease of distribution and substantial recurring utilization.

Although mature, this segment remains strategically relevant because hospital glucose monitoring alone requires repeated testing throughout the day for large numbers of patients. Future value growth will be more moderate than for molecular cartridges, but connected meters, improved hematocrit compensation, smaller sample requirements and quality-control integration will defend the segment.

Disposable Test Cassettes and Cards

Disposable cassettes and cards represent approximately USD 2.44 billion in 2025 and are widely used for respiratory infections, pregnancy, fertility, drugs of abuse and infectious-disease screening. Lateral-flow architecture allows manufacturers to produce inexpensive, room-temperature-stable tests that require minimal equipment.

The category is evolving toward multiplex and digitally interpreted products. Respiratory combination tests are especially important because one cassette can increasingly identify multiple viral targets, improving clinical value per patient encounter.

Single-Use Reagent and Molecular Cartridges

Single-use cartridges account for an estimated USD 2.87 billion in 2025 and are expected to record some of the strongest absolute revenue growth through 2035. These cartridges support rapid molecular diagnostics, blood gases, electrolytes, coagulation and immunoassays.

The business model is attractive because the durable analyzer creates a closed or semi-closed installed base, while revenue is generated by recurring cartridge consumption. Hospitals and urgent-care operators typically evaluate these systems on menu breadth, turnaround time, connectivity and cost per actionable result.

Microfluidic and Lab-on-Chip Devices

Microfluidic single-use devices represent approximately USD 1.06 billion in 2025. The segment is relatively smaller but strategically important because it enables sophisticated testing from finger-stick or otherwise low-volume specimens.

Growth will be supported by cardiometabolic assays, coagulation, immunoassay testing and emerging molecular applications. The ability to consolidate fluid handling into a disposable device reduces operator complexity and creates potential for testing in physician offices and pharmacies.

Integrated Collection-and-Test Devices

Integrated swab, sensor and specimen-collection test products account for an estimated USD 0.90 billion in 2025. This category is especially relevant to home testing and high-throughput infectious-disease workflows. Product innovation focuses on reducing transfer steps, minimizing contamination, simplifying instructions and improving first-time user success.

 

By Application

Infectious Disease Testing

Infectious disease testing is the largest application, accounting for approximately USD 3.93 billion in 2025. Respiratory testing remains the largest contributor, but the commercial model is evolving from high-volume COVID-only testing toward seasonal multiplex respiratory diagnostics.

Influenza A/B, SARS-CoV-2, RSV, Group A Streptococcus, HIV and sexually transmitted infection testing create a broad application base. Rapid testing has especially high value where treatment depends on early diagnosis or where losing a patient to follow-up creates clinical risk.

Diabetes and Metabolic Testing

Diabetes and metabolic testing represents approximately USD 3.08 billion in 2025. Blood glucose strips remain significant, while point-of-care HbA1c, ketones, lipid panels and related metabolic tests expand the addressable market.

The U.S. diabetes population creates a structurally recurring testing requirement. The category will experience competitive pressure from continuous glucose monitoring in home diabetes management, but acute-care and institutional blood glucose testing will remain substantial.

Cardiac and Coagulation Testing

Cardiac biomarker and coagulation applications account for approximately USD 1.38 billion in 2025. Troponin, BNP or NT-proBNP, D-dimer, INR and activated clotting time are examples of tests where rapid results can materially influence patient management.

Emergency departments, anticoagulation services and cardiovascular programs value point-of-care systems when faster turnaround affects treatment escalation or patient disposition. High-value cartridges with laboratory-comparable performance can command premium pricing when supported by strong clinical evidence.

Pregnancy, Fertility and Women’s Health Testing

Pregnancy, ovulation and women’s-health tests account for an estimated USD 1.06 billion in 2025. This is one of the most established consumer POC categories and benefits from high retail availability and strong user familiarity.

Innovation increasingly centers on digital interpretation, earlier detection, connected fertility management and expanded women’s-health testing beyond pregnancy alone.

Blood Gas, Electrolyte, Renal and Other Testing

Blood gas, electrolyte, renal, hematology and other specialty applications represent approximately USD 1.17 billion in 2025. These tests are particularly important in emergency, critical-care, perioperative and acute-care settings where minutes can matter clinically.

Creatinine and renal-function testing also has strategic relevance as kidney disease screening and medication-management requirements expand.

 

By Sample Type

Blood and Capillary Blood

Blood and capillary blood represent the largest sample segment, accounting for approximately USD 4.46 billion in 2025. Glucose, cardiac biomarkers, coagulation, HbA1c, blood gases, electrolytes and metabolic testing drive demand.

Finger-stick testing is particularly attractive outside hospitals because it avoids conventional phlebotomy and can provide adequate specimen volume for increasingly sophisticated microfluidic assays.

Nasal and Nasopharyngeal Samples

Nasal and nasopharyngeal testing represents approximately USD 2.87 billion in 2025, primarily driven by respiratory diagnostics. Anterior nasal collection gained significant consumer familiarity during the COVID-19 pandemic and is now an important format for multiplex home and professional respiratory testing.

Urine

Urine-based devices represent approximately USD 1.49 billion in 2025. Pregnancy, urinalysis, urinary tract infection screening, drugs-of-abuse testing and kidney-related applications support recurring demand across professional and consumer markets.

Saliva and Oral Fluid

Saliva and oral-fluid devices account for approximately USD 0.96 billion in 2025. Demand is concentrated in infectious-disease screening, oral-fluid drug testing and selected molecular applications. The non-invasive nature of collection is attractive, although assay sensitivity and specimen variability remain important design considerations.

Other Specimens

Other specimen types collectively represent approximately USD 0.84 billion in 2025 and include stool, vaginal specimens and specialty body fluids used in targeted POC applications.

 

By End-Use Setting

Hospitals and Emergency Departments

Hospitals and emergency departments represent the largest setting, generating approximately USD 3.61 billion in 2025. High testing intensity across emergency medicine, critical care, perioperative services, neonatal care, diabetes management and infectious diseases makes hospitals major consumers of disposable cartridges and strips.

Procurement is increasingly centralized through integrated delivery networks. Vendors must therefore demonstrate not only analytical performance but also interoperability, cybersecurity, quality-control capability, supply continuity and enterprise contracting economics.

Urgent-Care Centers and Physician Offices

Urgent care and physician practices account for approximately USD 2.44 billion in 2025 and represent one of the highest-potential settings. The U.S. urgent-care network now exceeds 15,000 centers and treats more than 100 million patients each year, creating substantial demand for respiratory, strep, pregnancy, urinalysis and other immediate diagnostics.

These providers require fast tests that fit short patient encounters. A delayed laboratory result can require a follow-up phone call or second visit, while a POC result can support diagnosis and treatment during the original encounter.

Home and Self-Testing

Home and self-testing represent approximately USD 2.12 billion in 2025. The segment includes glucose, pregnancy, fertility and infectious-disease products, with respiratory multiplexing expected to be a particularly important growth area.

Consumer adoption depends heavily on ease of specimen collection, instruction quality, accuracy, price and confidence in result interpretation. Digital support is likely to become a stronger differentiator through 2035.

Retail Pharmacies

Retail pharmacies represent approximately USD 1.27 billion in 2025. Pharmacy-based testing benefits from high geographic accessibility and the ability to connect testing with vaccination, referral, medication counseling and, where permitted, treatment pathways.

Pharmacy adoption can scale quickly when testing services are standardized across large chains, making national accounts strategically important for manufacturers.

Ambulatory, Community and Public-Health Settings

Ambulatory clinics, community health centers, public-health programs, schools, employer clinics and other decentralized environments account for approximately USD 1.18 billion in 2025. These settings favor portable, room-temperature-stable tests requiring little infrastructure.

 

By Technology

Lateral-Flow Immunoassays

Lateral-flow systems represent approximately USD 3.82 billion in 2025, making them the largest technology segment. Low manufacturing cost, rapid results, room-temperature storage and simplicity explain their extensive use.

The next growth cycle will emphasize multiplex designs, improved sensitivity and digital interpretation rather than conventional single-analyte cards alone.

Electrochemical Biosensors

Electrochemical biosensors account for approximately USD 2.97 billion in 2025, primarily supported by glucose and selected chemistry testing. The technology offers rapid quantitative results from small specimen volumes and remains deeply embedded in hospital and chronic-disease workflows.

Rapid Molecular Technologies

Rapid molecular single-use devices represent approximately USD 1.91 billion in 2025 and are expected to be the fastest-growing technology segment through 2035. PCR and other nucleic-acid amplification methods are moving closer to patients as cartridge automation reduces operator complexity.

The strongest opportunities involve multiplex respiratory testing, sexually transmitted infections and other applications where higher sensitivity materially affects treatment decisions.

Microfluidic Immunochemistry and Clinical Chemistry

Microfluidic immunochemistry and chemistry devices account for approximately USD 1.17 billion in 2025. Their ability to perform laboratory-like processes within compact disposable consumables makes them attractive for primary care and community diagnostics.

Optical, Colorimetric and Other Technologies

Other optical, colorimetric and emerging technologies represent approximately USD 0.75 billion in 2025. Growth will depend on improvements in digital image interpretation, miniaturized optics and smartphone-enabled reading systems.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Single-Use Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance is influenced by population scale, chronic disease prevalence, hospital density, urgent-care penetration, retail pharmacy infrastructure, infectious-disease patterns, rural access challenges, Medicaid policy, academic medical-center concentration and consumer adoption of home testing.

The South represents the largest regional market, while the West is expected to record the fastest CAGR through 2035. The Northeast remains a high-value market because of its dense provider infrastructure and rapid adoption of premium diagnostics, while the Midwest combines large health systems with significant chronic-disease and rural-care needs.

South

The South represents an estimated USD 3.93 billion in 2025, equivalent to approximately 37% of national revenue, and could approach USD 11.60 billion by 2035. The region includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and West Virginia, together with the District of Columbia.

Texas is one of the country’s most important individual POC testing markets. Its large population, rapidly expanding metropolitan areas and extensive hospital, urgent-care and retail networks create high demand for respiratory diagnostics, glucose testing, pregnancy tests, molecular cartridges and acute-care chemistry. Houston, Dallas–Fort Worth, Austin and San Antonio function as major healthcare purchasing hubs.

Florida is particularly attractive because of its large older population and substantial seasonal respiratory-disease burden. Diabetes, cardiovascular disease and renal impairment also support demand for chronic-disease and acute-care testing. Large health systems, urgent-care chains and senior-care networks create recurring cartridge utilization.

Georgia and North Carolina are increasingly important due to population growth, expanding metropolitan healthcare infrastructure and strong academic medical centers. Atlanta, Charlotte, Raleigh-Durham and other regional hubs provide favorable environments for molecular POC platforms and multi-site health-system contracting.

Tennessee has major healthcare delivery and management organizations headquartered around Nashville and strong clinical markets in Nashville, Memphis and Knoxville. Virginia and Maryland benefit from sophisticated provider systems, strong suburban healthcare spending and proximity to federal health institutions.

South Carolina, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma and West Virginia have substantial chronic-disease burdens that make accessible diabetes, renal, cardiovascular and infectious-disease testing particularly important. Rural provider shortages in several of these states improve the value proposition for decentralized testing because specimens may otherwise travel significant distances to centralized laboratories.

Delaware is smaller in absolute revenue but benefits from proximity to major Northeast healthcare markets, while the District of Columbia has a dense concentration of hospitals, specialist care and public-health infrastructure.

The South’s opportunity is therefore broader than population growth alone. It combines high disease burden with expanding outpatient infrastructure and some of the largest geographic access gaps in U.S. healthcare. Single-use devices that can be deployed without extensive laboratory staffing have particular strategic value in this environment.

West

The West accounts for approximately USD 2.44 billion in 2025 and is expected to reach approximately USD 7.70 billion by 2035, representing an estimated CAGR of approximately 12.2%, the fastest among the four regions. The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming.

California is the dominant Western state market and one of the country’s most attractive locations for next-generation decentralized diagnostics. Its scale, academic medical centers, integrated health systems, technology ecosystem and large biotechnology industry support early evaluation of microfluidics, connected diagnostic platforms and digital home-testing solutions.

The state’s healthcare market also creates demand across very different operating environments. Large metropolitan systems in Los Angeles, San Diego, San Francisco and Sacramento can adopt sophisticated cartridge-based technologies, while rural and agricultural areas benefit from portable testing that reduces laboratory transportation requirements.

Arizona and Nevada are high-growth markets because of population migration and increasing healthcare capacity. Their expanding older populations create demand for glucose, cardiac, renal and respiratory testing. Phoenix and Las Vegas have become important commercial territories for diagnostic manufacturers.

Washington and Oregon have strong integrated delivery systems and comparatively advanced digital-health adoption. These markets are particularly receptive to connected POC platforms capable of transferring results automatically into enterprise information systems.

Colorado and Utah combine population growth with strong health-system infrastructure and technology-oriented provider organizations. Denver, Salt Lake City and surrounding metropolitan areas are favorable early-adoption markets for rapid molecular and microfluidic testing.

New Mexico, Idaho, Montana and Wyoming demonstrate the importance of decentralized diagnostics for geographically dispersed populations. Rural communities may be located far from full-service laboratories, making portable POC testing valuable in community hospitals, physician practices and critical-access settings.

Alaska presents some of the country’s most extreme geographic access challenges. Single-use devices with long shelf life, simple workflows and limited cold-chain requirements can create significant clinical value in remote communities. Hawaii similarly benefits from decentralized testing because island geography complicates specimen transportation and laboratory consolidation.

The West is expected to gain national market share through 2035 because its growth drivers combine population expansion, health-technology adoption, rural diagnostic needs and consumer acceptance of digitally enabled healthcare.

Northeast

The Northeast accounts for approximately USD 2.34 billion in 2025 and could reach approximately USD 6.42 billion by 2035. The region includes Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont.

New York represents the largest state market in the region. New York City has one of the country’s densest networks of hospitals, outpatient practices, urgent-care locations and retail healthcare sites. The state also contains substantial Medicaid, public-health and community-clinic testing volumes.

Pennsylvania combines large metropolitan healthcare markets in Philadelphia and Pittsburgh with significant suburban and rural populations. This creates demand spanning high-acuity hospital testing, urgent-care respiratory diagnostics and decentralized rural care.

New Jersey benefits from high population density, substantial healthcare utilization and close integration with the New York and Philadelphia medical markets. The state’s life-sciences ecosystem also creates strong manufacturer and commercial infrastructure.

Massachusetts is particularly influential despite its smaller population. Boston’s academic medical centers, biotechnology companies and clinical-research institutions make the state a key early-evaluation environment for emerging molecular and microfluidic platforms.

Connecticut and Rhode Island offer dense health-system markets where enterprise standardization can generate strong cartridge pull-through. Maine, New Hampshire and Vermont are smaller markets, but rural access and aging populations make near-patient diagnostic capability strategically important.

The Northeast is not expected to grow as rapidly as the West because population growth is slower and the healthcare market is more mature. Nevertheless, high test utilization, strong reimbursement, academic medicine and rapid clinical adoption should preserve attractive revenue per testing site.

Midwest

The Midwest represents approximately USD 1.91 billion in 2025 and is projected to reach approximately USD 5.37 billion by 2035. The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota and Wisconsin.

Illinois is the region’s largest commercial hub, with Chicago supporting major academic hospitals, integrated delivery networks, physician groups and urgent-care operators. Respiratory testing, acute-care chemistry and cardiometabolic testing generate substantial recurring demand.

Ohio is another major market with large health systems and extensive hospital infrastructure. Cleveland, Columbus and Cincinnati create significant opportunities for enterprise POC contracting.

Michigan has a large chronic-disease burden and substantial hospital-based testing needs. Detroit and surrounding health systems are important markets for glucose, respiratory, cardiovascular and acute-care diagnostics.

Minnesota is strategically important because of its medical-technology ecosystem and highly integrated provider networks. The state is often relevant for product evaluation, clinical collaboration and adoption of connected diagnostic systems.

Indiana, Wisconsin and Missouri provide stable recurring demand across hospitals, ambulatory clinics and physician practices. Iowa, Kansas and Nebraska highlight the role of POC testing in mixed urban-rural healthcare systems.

North Dakota and South Dakota are relatively small markets by absolute revenue but illustrate one of the strongest clinical arguments for decentralized diagnostics: patients and specimens may need to travel long distances if testing cannot be performed locally.

The Midwest should remain a durable market through 2035. Vendors that combine competitive cost per test with strong service reliability, distributor coverage and easy-to-use systems are likely to perform well across the region.

 

Key Market Players

The U.S. Single-Use Point-of-Care Testing Devices Competitive Landscape is moderately consolidated in several high-volume categories but remains fragmented across specialty applications. Large diagnostics companies benefit from established hospital contracts, instrument placements, manufacturing scale, regulatory expertise and broad assay portfolios. Smaller manufacturers can compete effectively where they offer differentiated molecular testing, novel microfluidics, low-cost lateral-flow formats or highly focused disease applications.

Competition is increasingly based on recurring test-menu economics. A manufacturer with a larger installed analyzer base can leverage each placement across multiple disposable assays. Conversely, companies focused on analyzer-independent lateral-flow products compete through price, retailer relationships, private-label manufacturing, distribution and assay performance.

Some of the key participants in the U.S. market include Abbott Laboratories; Roche Diagnostics; Siemens Healthineers; Danaher Corporation through Cepheid and Radiometer/HemoCue; QuidelOrtho Corporation; Becton, Dickinson and Company; bioMérieux; Nova Biomedical; Werfen; EKF Diagnostics; OraSure Technologies; ACON Laboratories; Sekisui Diagnostics; Trinity Biotech; ARKRAY USA; LifeScan; Ascensia Diabetes Care; Healgen Scientific; Access Bio; GenBody America; bioLytical Laboratories; Binx Health; Visby Medical; and Cardinal Health.

Abbott maintains one of the strongest positions because its presence spans glucose testing, rapid lateral-flow diagnostics, infectious disease and molecular POC systems. Roche is strengthening its near-patient portfolio through the integration of LumiraDx’s point-of-care technology in addition to its established cobas liat molecular platform. Danaher’s Cepheid business remains influential in cartridge-based molecular diagnostics, while Radiometer and HemoCue support critical-care and hematology testing.

QuidelOrtho has a major installed base and brand presence in rapid infectious-disease testing. BD participates across multiple diagnostic and specimen-handling categories, while bioMérieux remains strategically important in infectious-disease diagnostics. Nova Biomedical and Werfen are relevant in hospital acute-care and coagulation workflows.

The competitive position of each manufacturer will increasingly depend on six capabilities: menu expansion, regulatory execution, manufacturing scalability, supply continuity, connectivity and health-economic evidence. The COVID-19 period demonstrated that diagnostic demand can change extraordinarily quickly. U.S. customers now place greater emphasis on whether suppliers can scale manufacturing and maintain dependable distribution during disease surges.

 

Recent Developments

The U.S. single-use POC market has entered a post-pandemic product-development cycle centered on multiplex diagnostics rather than COVID-only testing. In October 2024, the FDA granted traditional marketing authorization to an over-the-counter combination antigen test capable of detecting COVID-19 and influenza A and B from a nasal specimen in approximately 15 minutes. The development was commercially important because it demonstrated a regulatory pathway for home respiratory combination testing outside emergency-use mechanisms.

Roche completed its acquisition of LumiraDx’s point-of-care technology in July 2024. The transaction expanded Roche’s decentralized diagnostics capabilities across immunoassay, clinical chemistry and coagulation and strengthened its ability to compete for recurring single-use cartridge revenue in primary-care and near-patient environments.

The rapid molecular respiratory market has continued to broaden. FDA marketing authorizations during 2025 and 2026 expanded the availability of multi-analyte molecular tests capable of detecting combinations of SARS-CoV-2, influenza A/B and RSV. The continued introduction of CLIA-waived molecular products is strategically significant because it moves laboratory-level nucleic-acid testing closer to urgent care and physician-office workflows.

The competitive landscape is also being reshaped by portfolio rationalization. Diagnostic manufacturers are becoming more selective about which proprietary analyzer platforms they fund, particularly where R&D expense, menu-development cost and instrument-placement requirements are high. As a result, companies are prioritizing platforms capable of supporting multiple high-frequency assays instead of maintaining narrowly focused systems.

Home diagnostics are simultaneously moving from emergency-era products toward conventional regulated consumer healthcare. This transition should improve category durability because future growth will depend on repeatable clinical use cases rather than temporary public-health purchasing.

 

Conclusion

The U.S. Single-Use Point-of-Care Testing Devices Market Size & Share is positioned to increase from approximately USD 10.62 billion in 2025 to USD 31.09 billion by 2035, reflecting a projected 11.34% CAGR during 2026–2035.

Unlike the pandemic-era rapid-test market, the next growth cycle will be broader and more structurally diversified. Infectious-disease testing will remain the largest application, but future expansion will increasingly come from multiplex respiratory cartridges, rapid molecular testing, cardiometabolic diagnostics, microfluidic platforms, home testing and pharmacy-based healthcare.

Single-use economics make this market particularly attractive to diagnostics manufacturers. Instrument placement creates the installed base, but recurring strips, cassettes and cartridges create long-term revenue. Companies capable of expanding assay menus while maintaining high analyzer utilization can generate meaningful customer lifetime value and strengthen account retention.

Hospitals will remain the largest care setting, but a growing percentage of incremental volume will come from urgent care, physician offices, pharmacies and homes. This shift will place greater emphasis on CLIA-waived workflows, room-temperature storage, simple specimen handling, connectivity and low training requirements.

Geographically, the South will remain the largest regional market, supported by population scale, chronic disease burden and expanding outpatient infrastructure. The West is expected to record the fastest growth, supported by population migration, early technology adoption and decentralized care requirements. The Northeast will retain premium diagnostic intensity, while the Midwest will remain an important market for both integrated health systems and rural-access solutions.

For clients evaluating this industry, the key strategic question is not simply how many point-of-care tests will be performed. The more consequential question is which testing platforms can convert an installed analyzer base into sustained disposable utilization across multiple clinical applications.

The highest-value competitive positions through 2035 are likely to belong to companies that can combine rapid turnaround, strong analytical performance, broad assay menus, regulatory execution, dependable U.S. manufacturing or distribution, enterprise connectivity and convincing workflow economics. In this market, recurring consumable demand—and the clinical decisions those consumables enable—will ultimately determine where long-term value accumulates.

 

TABLE OF CONTENT

1. U.S. Single-Use Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Single-Use POC Testing Device Manufacturers
1.6.2. Reagent, Biosensor, Microfluidic and Cartridge Component Suppliers
1.6.3. Contract Manufacturing and Diagnostic Packaging Partners
1.6.4. Hospitals, Emergency Departments and Integrated Delivery Networks
1.6.5. Urgent-Care Centers and Physician Office Laboratories
1.6.6. Retail Pharmacies, Home-Testing Channels and Consumer Health Platforms
1.6.7. Distributors, Group Purchasing Organizations and Laboratory Suppliers
1.6.8. FDA, CMS, CLIA Authorities, Payers and Clinical Decision-Makers

What this section provides: This section defines the market boundary, inclusion and exclusion criteria, study scope, methodology, assumptions and stakeholder ecosystem so clients understand how the U.S. Single-Use Point-of-Care Testing Devices Market is measured, segmented and validated.

2. U.S. Single-Use Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. High-Growth Opportunity Areas
2.9. Fastest-Growing Product and Testing Formats
2.10. Key Investment and Commercialization Themes

What this section provides: This section gives decision-makers a concise view of market size, historical development, forecast growth, high-value testing applications, competitive intensity and priority commercial opportunities through 2035.

3. U.S. Single-Use Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of Decentralized and Near-Patient Diagnostic Testing
3.1.2. Growing Installed Base of CLIA-Waived Testing Sites
3.1.3. Rising Demand for Rapid Multiplex Respiratory Testing
3.1.4. Increasing Diabetes and Chronic Disease Testing Burden
3.1.5. Growth of Urgent-Care and Physician Office Testing
3.1.6. Expansion of Home and Over-the-Counter Diagnostic Testing
3.1.7. Recurring Consumables Revenue from Cartridge-Based Platforms
3.1.8. Increasing Need for Faster Clinical Decision-Making
3.2. Restraints and Their Impact Analysis
3.2.1. Cost Per Test Versus Central Laboratory Testing
3.2.2. Reimbursement Variability Across Testing Applications
3.2.3. Accuracy and Performance Concerns in Low-Complexity Testing
3.2.4. Operator Training and Quality-Control Requirements
3.2.5. Competitive Pricing Pressure in Mature Lateral-Flow Categories
3.2.6. Environmental Burden of High-Volume Disposable Diagnostic Waste
3.3. Opportunities and Their Impact Analysis
3.3.1. Multiplex Respiratory Test Expansion
3.3.2. Rapid Molecular Testing at CLIA-Waived Sites
3.3.3. Microfluidic and Lab-on-Chip Diagnostics
3.3.4. Pharmacy-Based Diagnostic and Test-to-Treat Models
3.3.5. At-Home Molecular and Connected Self-Testing
3.3.6. Cardiometabolic and Renal Disease Screening
3.3.7. Expansion into Rural and Underserved Care Settings
3.3.8. Digital Interpretation and EHR-Connected Point-of-Care Testing
3.4. Challenges and Their Impact Analysis
3.4.1. Supply-Chain Continuity and Seasonal Demand Volatility
3.4.2. Regulatory Complexity Across Professional and OTC Tests
3.4.3. Maintaining Test Accuracy Outside Central Laboratories
3.4.4. Platform Lock-In Versus Open-System Procurement
3.4.5. Balancing Disposable Convenience with Sustainability Requirements
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Cost-Per-Result and Total Testing Economics
3.8. Analyzer Placement and Consumables Pull-Through Analysis
3.9. Healthcare Provider Procurement Behavior Analysis

What this section provides: This section evaluates the clinical, commercial, reimbursement, technology and operational forces shaping single-use POC test consumption and helps clients assess growth opportunities alongside execution, pricing and adoption risks.

4. U.S. Single-Use Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Raw Materials and Diagnostic Reagents
4.4.2. Biosensors and Microfluidic Components
4.4.3. Cartridge, Strip and Cassette Manufacturing
4.4.4. Diagnostic Device OEMs
4.4.5. Distributors and GPO Networks
4.4.6. Professional and Consumer Testing Channels
4.5. Impact of Digitalization and Connected Diagnostics
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. 510(k) Pathway
4.7.2. De Novo Classification
4.7.3. PMA Considerations
4.7.4. OTC Diagnostic Authorization
4.7.5. Emergency Use Authorization Lessons and Transition
4.8. CLIA Waiver and Laboratory Testing Framework
4.9. CMS Reimbursement and Coverage Landscape
4.10. CPT Coding and Payment Considerations
4.11. Import/Export Restrictions & Tariff Impact
4.12. U.S. Public Health and Decentralized Testing Programs
4.13. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.14. Health System Value Analysis and Procurement Decision Framework
4.15. Single-Use Diagnostic Waste and Sustainability Analysis

What this section provides: This section provides a comprehensive assessment of regulation, CLIA requirements, reimbursement, pricing, supply chain, technology adoption, sustainability and purchasing dynamics affecting commercial success in the U.S. single-use POC testing industry.

5. U.S. Single-Use Point-of-Care Testing Devices Market – By Product Format

5.1. Overview
5.1.1. Segment Share Analysis, By Product Format, 2025 & 2035 (%)
5.1.2. Test Strips and Dipsticks
5.1.3. Disposable Test Cassettes and Cards
5.1.4. Single-Use Reagent and Molecular Cartridges
5.1.5. Microfluidic and Lab-on-Chip Devices
5.1.6. Integrated Collection-and-Test Devices

What this section provides: This section identifies which disposable test formats contribute the greatest recurring revenue and which formats are expected to gain share as POC testing becomes more automated, multiplexed and decentralized.

6. U.S. Single-Use Point-of-Care Testing Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Infectious Disease Testing
6.1.2.1. COVID-19 Testing
6.1.2.2. Influenza A & B Testing
6.1.2.3. RSV Testing
6.1.2.4. Multiplex Respiratory Testing
6.1.2.5. Group A Streptococcus Testing
6.1.2.6. HIV Testing
6.1.2.7. Sexually Transmitted Infection Testing
6.1.2.8. Other Infectious Disease Tests
6.1.3. Diabetes and Metabolic Testing
6.1.3.1. Blood Glucose Testing
6.1.3.2. HbA1c Testing
6.1.3.3. Ketone Testing
6.1.3.4. Lipid and Metabolic Panel Testing
6.1.4. Cardiac and Coagulation Testing
6.1.4.1. Cardiac Troponin Testing
6.1.4.2. BNP/NT-proBNP Testing
6.1.4.3. D-Dimer Testing
6.1.4.4. PT/INR Testing
6.1.4.5. Activated Clotting Time Testing
6.1.5. Pregnancy, Fertility and Women’s Health Testing
6.1.5.1. Pregnancy Testing
6.1.5.2. Ovulation and Fertility Testing
6.1.5.3. Other Women’s Health Tests
6.1.6. Blood Gas, Electrolyte, Renal and Other Testing
6.1.6.1. Blood Gas Testing
6.1.6.2. Electrolyte Testing
6.1.6.3. Creatinine and Renal Function Testing
6.1.6.4. Urinalysis
6.1.6.5. Drugs-of-Abuse Testing
6.1.6.6. Other POC Testing Applications

What this section provides: This section measures demand by clinical application and helps clients identify test categories with the strongest testing frequency, reimbursement potential, seasonal utilization and future product-development opportunities.

7. U.S. Single-Use Point-of-Care Testing Devices Market – By Sample Type

7.1. Overview
7.1.1. Segment Share Analysis, By Sample Type, 2025 & 2035 (%)
7.1.2. Blood and Capillary Blood
7.1.2.1. Finger-Stick Blood
7.1.2.2. Venous Whole Blood
7.1.2.3. Plasma and Serum-Compatible POC Formats
7.1.3. Nasal and Nasopharyngeal Samples
7.1.3.1. Anterior Nasal Samples
7.1.3.2. Mid-Turbinate Samples
7.1.3.3. Nasopharyngeal Samples
7.1.4. Urine
7.1.5. Saliva and Oral Fluid
7.1.6. Other Specimens
7.1.6.1. Vaginal and Genital Specimens
7.1.6.2. Stool Samples
7.1.6.3. Other Body Fluids

What this section provides: This section evaluates specimen-specific demand, sample-collection complexity, user convenience, clinical suitability and innovation opportunities across professional and self-testing environments.

8. U.S. Single-Use Point-of-Care Testing Devices Market – By End-Use Setting

8.1. Overview
8.1.1. Segment Share Analysis, By End-Use Setting, 2025 & 2035 (%)
8.1.2. Hospitals and Emergency Departments
8.1.2.1. Emergency Departments
8.1.2.2. Intensive and Critical Care Units
8.1.2.3. Inpatient Units
8.1.2.4. Perioperative and Surgical Care
8.1.3. Urgent-Care Centers and Physician Offices
8.1.3.1. Urgent-Care Centers
8.1.3.2. Primary-Care Practices
8.1.3.3. Specialist Physician Offices
8.1.3.4. Physician Office Laboratories
8.1.4. Home and Self-Testing
8.1.4.1. OTC Retail Home Testing
8.1.4.2. Direct-to-Consumer Testing
8.1.4.3. Remote and Connected Home Testing
8.1.5. Retail Pharmacies
8.1.5.1. National Pharmacy Chains
8.1.5.2. Regional and Independent Pharmacies
8.1.5.3. Pharmacy Test-to-Treat Programs
8.1.6. Ambulatory, Community and Public-Health Settings
8.1.6.1. Ambulatory Clinics
8.1.6.2. Community Health Centers
8.1.6.3. Public Health and Mobile Testing Programs
8.1.6.4. Employer and Occupational Health Clinics
8.1.6.5. Schools and Other Decentralized Testing Sites

What this section provides: This section identifies where single-use tests are consumed, how testing economics differ by setting and which decentralized care channels are expected to generate the strongest incremental test volumes through 2035.

9. U.S. Single-Use Point-of-Care Testing Devices Market – By Technology

9.1. Overview
9.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
9.1.2. Lateral-Flow Immunoassays
9.1.2.1. Visual Lateral-Flow Tests
9.1.2.2. Reader-Assisted Lateral-Flow Tests
9.1.2.3. Multiplex Lateral-Flow Tests
9.1.3. Electrochemical Biosensors
9.1.3.1. Enzymatic Biosensors
9.1.3.2. Electrochemical Strip-Based Systems
9.1.3.3. Single-Use Sensor Cartridges
9.1.4. Rapid Molecular Technologies
9.1.4.1. PCR-Based POC Testing
9.1.4.2. Isothermal Nucleic Acid Amplification
9.1.4.3. Multiplex Molecular Cartridges
9.1.4.4. Other Rapid Molecular Technologies
9.1.5. Microfluidic Immunochemistry and Clinical Chemistry
9.1.5.1. Microfluidic Immunoassays
9.1.5.2. Microfluidic Clinical Chemistry
9.1.5.3. Lab-on-Chip Platforms
9.1.6. Optical, Colorimetric and Other Technologies
9.1.6.1. Optical Detection
9.1.6.2. Colorimetric Detection
9.1.6.3. Smartphone-Assisted Test Interpretation
9.1.6.4. Emerging Single-Use Detection Technologies

What this section provides: This section evaluates the core diagnostic technologies driving test performance, turnaround time, workflow simplicity and future differentiation across disposable POC platforms.

10. U.S. Single-Use Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Testing Volume and Healthcare Infrastructure Analysis
10.1.4. Regional CLIA-Waived Site and Decentralized Testing Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Urgent-Care, Pharmacy and Home-Testing Adoption
10.1.7. Regional Disease Burden and Diagnostic Demand Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, Distributors and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Format, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End-Use Setting, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Format, 2021–2035
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035
10.2.9.4. California Market Size and Forecast, By Sample Type, 2021–2035
10.2.9.5. California Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.9.6. California Market Size and Forecast, By Technology, 2021–2035
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Format, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By Sample Type, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.10.6. Washington Market Size and Forecast, By Technology, 2021–2035
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Format, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By Sample Type, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.11.6. Arizona Market Size and Forecast, By Technology, 2021–2035
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Format, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By Sample Type, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.12.6. Colorado Market Size and Forecast, By Technology, 2021–2035
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Format, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By Sample Type, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.13.6. Oregon Market Size and Forecast, By Technology, 2021–2035
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Format, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By Sample Type, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.14.6. Utah Market Size and Forecast, By Technology, 2021–2035
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Format, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By Sample Type, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.15.6. Nevada Market Size and Forecast, By Technology, 2021–2035
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Format, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By Sample Type, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.16.6. New Mexico Market Size and Forecast, By Technology, 2021–2035
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Format, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By Sample Type, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.17.6. Idaho Market Size and Forecast, By Technology, 2021–2035
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Format, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By Sample Type, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.18.6. Montana Market Size and Forecast, By Technology, 2021–2035
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Format, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By Sample Type, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.19.6. Wyoming Market Size and Forecast, By Technology, 2021–2035
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Format, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By Sample Type, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.20.6. Alaska Market Size and Forecast, By Technology, 2021–2035
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Format, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By Sample Type, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By End-Use Setting, 2021–2035
10.2.21.6. Hawaii Market Size and Forecast, By Technology, 2021–2035
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, Distributors and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Format, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By Sample Type, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.8. Northeast Region Market Size and Forecast, By Technology, 2021–2035
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Format, 2021–2035
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035
10.3.9.4. New York Market Size and Forecast, By Sample Type, 2021–2035
10.3.9.5. New York Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.9.6. New York Market Size and Forecast, By Technology, 2021–2035
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Format, 2021–2035
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035
10.3.10.4. Massachusetts Market Size and Forecast, By Sample Type, 2021–2035
10.3.10.5. Massachusetts Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.10.6. Massachusetts Market Size and Forecast, By Technology, 2021–2035
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Format, 2021–2035
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035
10.3.11.4. New Jersey Market Size and Forecast, By Sample Type, 2021–2035
10.3.11.5. New Jersey Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.11.6. New Jersey Market Size and Forecast, By Technology, 2021–2035
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Format, 2021–2035
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035
10.3.12.4. Pennsylvania Market Size and Forecast, By Sample Type, 2021–2035
10.3.12.5. Pennsylvania Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.12.6. Pennsylvania Market Size and Forecast, By Technology, 2021–2035
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Format, 2021–2035
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035
10.3.13.4. Connecticut Market Size and Forecast, By Sample Type, 2021–2035
10.3.13.5. Connecticut Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.13.6. Connecticut Market Size and Forecast, By Technology, 2021–2035
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Format, 2021–2035
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035
10.3.14.4. Maine Market Size and Forecast, By Sample Type, 2021–2035
10.3.14.5. Maine Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.14.6. Maine Market Size and Forecast, By Technology, 2021–2035
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Format, 2021–2035
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035
10.3.15.4. Vermont Market Size and Forecast, By Sample Type, 2021–2035
10.3.15.5. Vermont Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.15.6. Vermont Market Size and Forecast, By Technology, 2021–2035
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Format, 2021–2035
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035
10.3.16.4. New Hampshire Market Size and Forecast, By Sample Type, 2021–2035
10.3.16.5. New Hampshire Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.16.6. New Hampshire Market Size and Forecast, By Technology, 2021–2035
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Format, 2021–2035
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035
10.3.17.4. Rhode Island Market Size and Forecast, By Sample Type, 2021–2035
10.3.17.5. Rhode Island Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.17.6. Rhode Island Market Size and Forecast, By Technology, 2021–2035
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Format, 2021–2035
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035
10.3.18.4. Delaware Market Size and Forecast, By Sample Type, 2021–2035
10.3.18.5. Delaware Market Size and Forecast, By End-Use Setting, 2021–2035
10.3.18.6. Delaware Market Size and Forecast, By Technology, 2021–2035
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, Distributors and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Format, 2021–2035
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035
10.4.6. South Region Market Size and Forecast, By Sample Type, 2021–2035
10.4.7. South Region Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.8. South Region Market Size and Forecast, By Technology, 2021–2035
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Format, 2021–2035
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035
10.4.9.4. Texas Market Size and Forecast, By Sample Type, 2021–2035
10.4.9.5. Texas Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.9.6. Texas Market Size and Forecast, By Technology, 2021–2035
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Format, 2021–2035
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035
10.4.10.4. Florida Market Size and Forecast, By Sample Type, 2021–2035
10.4.10.5. Florida Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.10.6. Florida Market Size and Forecast, By Technology, 2021–2035
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Format, 2021–2035
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035
10.4.11.4. Georgia Market Size and Forecast, By Sample Type, 2021–2035
10.4.11.5. Georgia Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.11.6. Georgia Market Size and Forecast, By Technology, 2021–2035
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Format, 2021–2035
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035
10.4.12.4. North Carolina Market Size and Forecast, By Sample Type, 2021–2035
10.4.12.5. North Carolina Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.12.6. North Carolina Market Size and Forecast, By Technology, 2021–2035
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Format, 2021–2035
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035
10.4.13.4. Tennessee Market Size and Forecast, By Sample Type, 2021–2035
10.4.13.5. Tennessee Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.13.6. Tennessee Market Size and Forecast, By Technology, 2021–2035
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Format, 2021–2035
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035
10.4.14.4. South Carolina Market Size and Forecast, By Sample Type, 2021–2035
10.4.14.5. South Carolina Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.14.6. South Carolina Market Size and Forecast, By Technology, 2021–2035
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Format, 2021–2035
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035
10.4.15.4. Alabama Market Size and Forecast, By Sample Type, 2021–2035
10.4.15.5. Alabama Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.15.6. Alabama Market Size and Forecast, By Technology, 2021–2035
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Format, 2021–2035
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035
10.4.16.4. Mississippi Market Size and Forecast, By Sample Type, 2021–2035
10.4.16.5. Mississippi Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.16.6. Mississippi Market Size and Forecast, By Technology, 2021–2035
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Format, 2021–2035
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035
10.4.17.4. Louisiana Market Size and Forecast, By Sample Type, 2021–2035
10.4.17.5. Louisiana Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.17.6. Louisiana Market Size and Forecast, By Technology, 2021–2035
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Format, 2021–2035
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035
10.4.18.4. Arkansas Market Size and Forecast, By Sample Type, 2021–2035
10.4.18.5. Arkansas Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.18.6. Arkansas Market Size and Forecast, By Technology, 2021–2035
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Format, 2021–2035
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035
10.4.19.4. Kentucky Market Size and Forecast, By Sample Type, 2021–2035
10.4.19.5. Kentucky Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.19.6. Kentucky Market Size and Forecast, By Technology, 2021–2035
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Format, 2021–2035
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035
10.4.20.4. Oklahoma Market Size and Forecast, By Sample Type, 2021–2035
10.4.20.5. Oklahoma Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.20.6. Oklahoma Market Size and Forecast, By Technology, 2021–2035
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Format, 2021–2035
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035
10.4.21.4. Virginia Market Size and Forecast, By Sample Type, 2021–2035
10.4.21.5. Virginia Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.21.6. Virginia Market Size and Forecast, By Technology, 2021–2035
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Format, 2021–2035
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035
10.4.22.4. Maryland Market Size and Forecast, By Sample Type, 2021–2035
10.4.22.5. Maryland Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.22.6. Maryland Market Size and Forecast, By Technology, 2021–2035
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Format, 2021–2035
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035
10.4.23.4. West Virginia Market Size and Forecast, By Sample Type, 2021–2035
10.4.23.5. West Virginia Market Size and Forecast, By End-Use Setting, 2021–2035
10.4.23.6. West Virginia Market Size and Forecast, By Technology, 2021–2035
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, Distributors and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Format, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By Sample Type, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.8. Midwest Region Market Size and Forecast, By Technology, 2021–2035
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Format, 2021–2035
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035
10.5.9.4. Illinois Market Size and Forecast, By Sample Type, 2021–2035
10.5.9.5. Illinois Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.9.6. Illinois Market Size and Forecast, By Technology, 2021–2035
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Format, 2021–2035
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035
10.5.10.4. Ohio Market Size and Forecast, By Sample Type, 2021–2035
10.5.10.5. Ohio Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.10.6. Ohio Market Size and Forecast, By Technology, 2021–2035
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Format, 2021–2035
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035
10.5.11.4. Michigan Market Size and Forecast, By Sample Type, 2021–2035
10.5.11.5. Michigan Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.11.6. Michigan Market Size and Forecast, By Technology, 2021–2035
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Format, 2021–2035
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035
10.5.12.4. Minnesota Market Size and Forecast, By Sample Type, 2021–2035
10.5.12.5. Minnesota Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.12.6. Minnesota Market Size and Forecast, By Technology, 2021–2035
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Format, 2021–2035
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035
10.5.13.4. Indiana Market Size and Forecast, By Sample Type, 2021–2035
10.5.13.5. Indiana Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.13.6. Indiana Market Size and Forecast, By Technology, 2021–2035
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Format, 2021–2035
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035
10.5.14.4. Wisconsin Market Size and Forecast, By Sample Type, 2021–2035
10.5.14.5. Wisconsin Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.14.6. Wisconsin Market Size and Forecast, By Technology, 2021–2035
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Format, 2021–2035
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035
10.5.15.4. Missouri Market Size and Forecast, By Sample Type, 2021–2035
10.5.15.5. Missouri Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.15.6. Missouri Market Size and Forecast, By Technology, 2021–2035
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Format, 2021–2035
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035
10.5.16.4. Iowa Market Size and Forecast, By Sample Type, 2021–2035
10.5.16.5. Iowa Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.16.6. Iowa Market Size and Forecast, By Technology, 2021–2035
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Format, 2021–2035
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035
10.5.17.4. Kansas Market Size and Forecast, By Sample Type, 2021–2035
10.5.17.5. Kansas Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.17.6. Kansas Market Size and Forecast, By Technology, 2021–2035
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Format, 2021–2035
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035
10.5.18.4. Nebraska Market Size and Forecast, By Sample Type, 2021–2035
10.5.18.5. Nebraska Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.18.6. Nebraska Market Size and Forecast, By Technology, 2021–2035
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Format, 2021–2035
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035
10.5.19.4. North Dakota Market Size and Forecast, By Sample Type, 2021–2035
10.5.19.5. North Dakota Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.19.6. North Dakota Market Size and Forecast, By Technology, 2021–2035
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Format, 2021–2035
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035
10.5.20.4. South Dakota Market Size and Forecast, By Sample Type, 2021–2035
10.5.20.5. South Dakota Market Size and Forecast, By End-Use Setting, 2021–2035
10.5.20.6. South Dakota Market Size and Forecast, By Technology, 2021–2035

What this section provides: This section delivers detailed regional and all-50-state analysis, allowing clients to identify high-volume testing markets, decentralized-care hotspots, CLIA-waived testing opportunities, regional adoption differences and state-level commercial priorities.

11. U.S. Single-Use Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Abbott Laboratories
11.3.2. Roche Diagnostics
11.3.3. Siemens Healthineers
11.3.4. Danaher Corporation
11.3.5. QuidelOrtho Corporation
11.3.6. Becton, Dickinson and Company
11.3.7. bioMérieux
11.3.8. Nova Biomedical
11.3.9. Werfen
11.3.10. EKF Diagnostics
11.3.11. OraSure Technologies
11.3.12. ACON Laboratories
11.3.13. Sekisui Diagnostics
11.3.14. Trinity Biotech
11.3.15. ARKRAY
11.3.16. LifeScan
11.3.17. Ascensia Diabetes Care
11.3.18. Healgen Scientific
11.3.19. Access Bio
11.3.20. GenBody America
11.3.21. bioLytical Laboratories
11.3.22. Binx Health
11.3.23. Visby Medical
11.3.24. Cardinal Health
11.3.25. PTS Diagnostics
11.4. Company Benchmarking Criteria
11.4.1. Single-Use Product Portfolio
11.4.2. POC Analyzer Installed Base
11.4.3. Disposable Cartridge and Test Menu Breadth
11.4.4. U.S. Regulatory Approvals and CLIA Waivers
11.4.5. Distribution and Retail Access
11.4.6. Manufacturing and Supply-Chain Capacity
11.4.7. Digital Connectivity Capabilities
11.4.8. Partnerships, M&A and Product Pipeline

Note: Each company profile will include company overview, U.S. single-use POC testing portfolio, core disposable formats, installed analyzer strategy where applicable, regulatory positioning, commercial footprint, partnerships, product launches, M&A activity and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, disposable-test portfolio positioning, installed-base economics, innovation direction and strategic intelligence on 25 major and emerging participants.

12. U.S. Single-Use Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multiplex Rapid Molecular Diagnostics
12.2.2. Next-Generation Microfluidic and Lab-on-Chip Platforms
12.2.3. Digitally Read Lateral-Flow Assays
12.2.4. Smartphone-Connected and App-Assisted Self-Testing
12.2.5. AI-Assisted Result Interpretation
12.2.6. Integrated Sample Collection and Testing Devices
12.2.7. Connected POC Quality-Control and Data Management
12.2.8. Low-Waste and Sustainable Disposable Diagnostic Platforms
12.3. Emerging Business Trends
12.3.1. Analyzer Placement and Recurring Cartridge Revenue Models
12.3.2. Expansion of Test-to-Treat Models
12.3.3. Consumerization of Diagnostics
12.3.4. Pharmacy and Retail Healthcare Expansion
12.3.5. Shift from Single-Analyte to Multiplex Testing
12.3.6. Decentralization of Laboratory Testing
12.3.7. U.S. Manufacturing and Supply Resilience
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Attractiveness Matrix
12.7. Application Opportunity Matrix
12.8. End-Use Expansion Opportunity Analysis

What this section provides: This section prepares clients for future technology shifts, diagnostic decentralization, changing testing economics, investment priorities and alternative market-development scenarios through 2035.

13. U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Diagnostic Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Urgent-Care and Physician Office Networks
13.4. Recommendations for Retail Pharmacy and Consumer Health Companies
13.5. Recommendations for Investors and Private Equity Firms
13.6. Recommendations for Distributors and Channel Partners
13.7. Recommendations for New Entrants and Diagnostic Startups
13.8. Go-to-Market Strategy Considerations
13.9. Regulatory and CLIA-Waiver Strategy Considerations
13.10. Analyzer Placement and Cartridge Pull-Through Strategy
13.11. Product Positioning and Assay Menu Expansion Guidance
13.12. U.S. Geographic Expansion Priorities
13.13. Partnership, Licensing and M&A Considerations

What this section provides: This section converts market intelligence into actionable strategy for product development, regulatory planning, assay-menu expansion, channel strategy, geographic prioritization, investment decisions and competitive differentiation.

14. U.S. Single-Use Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Market Definition and Revenue Attribution Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope limitations, market-sizing boundaries, forecasting assumptions, data-use conditions and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Single-Use Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Single-Use Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Single-Use Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Single-Use Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Single-Use Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Single-Use Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Single-Use Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Single-Use Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Single-Use Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Single-Use Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Single-Use Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Single-Use Point-of-Care Testing Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Single-Use Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Single-Use Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Single-Use Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Single-Use Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Single-Use Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Single-Use Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Single-Use Point-of-Care Testing Devices Market: Cost-Per-Result Economics Analysis
TABLE 21: U.S. Single-Use Point-of-Care Testing Devices Market: Analyzer Placement and Consumables Pull-Through Matrix
TABLE 22: U.S. Single-Use Point-of-Care Testing Devices Market: Healthcare Provider Procurement Behavior Matrix
TABLE 23: U.S. Single-Use Point-of-Care Testing Devices Market: Decentralized Testing Adoption Analysis
TABLE 24: U.S. Single-Use Point-of-Care Testing Devices Market: CLIA-Waived Testing Opportunity Matrix
TABLE 25: U.S. Single-Use Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 26: U.S. Single-Use Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 27: U.S. Single-Use Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 28: U.S. Single-Use Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 29: U.S. Single-Use Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 30: U.S. Single-Use Point-of-Care Testing Devices Market: Digitalization and Connected Diagnostics Impact
TABLE 31: U.S. Single-Use Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 32: U.S. Single-Use Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 33: U.S. Single-Use Point-of-Care Testing Devices Market: CLIA Waiver and Laboratory Testing Framework
TABLE 34: U.S. Single-Use Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 35: U.S. Single-Use Point-of-Care Testing Devices Market: CPT Coding and Payment Considerations
TABLE 36: U.S. Single-Use Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. Single-Use Point-of-Care Testing Devices Market: U.S. Public Health and Decentralized Testing Programs
TABLE 38: U.S. Single-Use Point-of-Care Testing Devices Market: Geopolitical and Supply-Chain Risk Analysis
TABLE 39: U.S. Single-Use Point-of-Care Testing Devices Market: Sustainability and Single-Use Diagnostic Waste Analysis
TABLE 40: U.S. Single-Use Point-of-Care Testing Devices Market: Product Format Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Format
TABLE 42: U.S. Single-Use Point-of-Care Testing Devices Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 43: U.S. Single-Use Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Format, 2025 & 2035 (%)
TABLE 44: Test Strips and Dipsticks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Disposable Test Cassettes and Cards Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Single-Use Reagent and Molecular Cartridges Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: Microfluidic and Lab-on-Chip Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Integrated Collection-and-Test Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Single-Use Point-of-Care Testing Devices Market: Application Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Application
TABLE 51: U.S. Single-Use Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 52: U.S. Single-Use Point-of-Care Testing Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 53: Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Diabetes and Metabolic Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Cardiac and Coagulation Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Pregnancy, Fertility and Women’s Health Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Blood Gas, Electrolyte, Renal and Other Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: Infectious Disease Testing Market, by Test Type, 2021–2035 (US$ Billion)
TABLE 59: Diabetes and Metabolic Testing Market, by Test Type, 2021–2035 (US$ Billion)
TABLE 60: Cardiac and Coagulation Testing Market, by Test Type, 2021–2035 (US$ Billion)
TABLE 61: U.S. Single-Use Point-of-Care Testing Devices Market: Sample Type Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Sample Type
TABLE 63: U.S. Single-Use Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 64: U.S. Single-Use Point-of-Care Testing Devices Market: Segment Share Analysis, by Sample Type, 2025 & 2035 (%)
TABLE 65: Blood and Capillary Blood Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: Nasal and Nasopharyngeal Samples Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: Urine Sample Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Saliva and Oral Fluid Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Other Specimen Types Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Single-Use Point-of-Care Testing Devices Market: End-Use Setting Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by End-Use Setting
TABLE 72: U.S. Single-Use Point-of-Care Testing Devices Market, by End-Use Setting, 2021–2035 (US$ Billion)
TABLE 73: U.S. Single-Use Point-of-Care Testing Devices Market: Segment Share Analysis, by End-Use Setting, 2025 & 2035 (%)
TABLE 74: Hospitals and Emergency Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Urgent-Care Centers and Physician Offices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: Home and Self-Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Retail Pharmacies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Ambulatory, Community and Public-Health Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Single-Use Point-of-Care Testing Devices Market: Technology Snapshot, 2025
TABLE 80: Segment Dashboard; Definition and Scope, by Technology
TABLE 81: U.S. Single-Use Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 82: U.S. Single-Use Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 83: Lateral-Flow Immunoassays Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: Electrochemical Biosensors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: Rapid Molecular Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: Microfluidic Immunochemistry and Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Optical, Colorimetric and Other Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: U.S. Single-Use Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 89: Segment Dashboard; Definition and Scope, by Region
TABLE 90: U.S. Single-Use Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 91: U.S. Single-Use Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 92: U.S. Single-Use Point-of-Care Testing Devices Market: Regional Testing Volume and Healthcare Infrastructure Analysis
TABLE 93: U.S. Single-Use Point-of-Care Testing Devices Market: Regional CLIA-Waived Testing and Procurement Dynamics
TABLE 94: West Region U.S. Single-Use Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 95: West Region U.S. Single-Use Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 96: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by End-Use Setting, 2021–2035 (US$ Billion)
TABLE 101: West Region U.S. Single-Use Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 102: California Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Washington Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Arizona Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Colorado Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Oregon Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Utah Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Nevada Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 109: New Mexico Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Idaho Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Montana Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Wyoming Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Alaska Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Hawaii Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 116: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 117: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 118: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 119: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 121: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by End-Use Setting, 2021–2035 (US$ Billion)
TABLE 122: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 123: New York Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Massachusetts Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 125: New Jersey Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Pennsylvania Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Connecticut Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Maine Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Vermont Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 130: New Hampshire Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Rhode Island Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Single-Use Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 133: South Region U.S. Single-Use Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 134: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 135: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 138: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by End-Use Setting, 2021–2035 (US$ Billion)
TABLE 139: South Region U.S. Single-Use Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 140: Texas Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Florida Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Georgia Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 143: North Carolina Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Tennessee Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 145: South Carolina Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Alabama Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Mississippi Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Louisiana Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Arkansas Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Kentucky Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Oklahoma Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Virginia Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Maryland Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 154: West Virginia Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Delaware Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 157: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 158: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by Product Format, 2021–2035 (US$ Billion)
TABLE 160: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 161: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 162: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by End-Use Setting, 2021–2035 (US$ Billion)
TABLE 163: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 164: Illinois Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Ohio Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Michigan Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Minnesota Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Indiana Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Wisconsin Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Missouri Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Iowa Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 172: Kansas Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 173: Nebraska Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 174: North Dakota Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 175: South Dakota Single-Use Point-of-Care Testing Devices Market: Market Dashboard and Forecast, 2021–2035 (US$ Billion)
TABLE 176: U.S. Single-Use Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 177: U.S. Single-Use Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 178: U.S. Single-Use Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 179: U.S. Single-Use Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 180: U.S. Single-Use Point-of-Care Testing Devices Market: Analyzer Installed Base and Consumables Strategy Benchmarking
TABLE 181: U.S. Single-Use Point-of-Care Testing Devices Market: Regulatory and CLIA-Waiver Benchmarking
TABLE 182: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 183: Abbott Laboratories: Company Profile
TABLE 184: Roche Diagnostics: Company Profile
TABLE 185: Siemens Healthineers: Company Profile
TABLE 186: Danaher Corporation: Company Profile
TABLE 187: QuidelOrtho Corporation: Company Profile
TABLE 188: Becton, Dickinson and Company: Company Profile
TABLE 189: bioMérieux: Company Profile
TABLE 190: Nova Biomedical: Company Profile
TABLE 191: Werfen: Company Profile
TABLE 192: EKF Diagnostics: Company Profile
TABLE 193: OraSure Technologies: Company Profile
TABLE 194: ACON Laboratories: Company Profile
TABLE 195: Sekisui Diagnostics: Company Profile
TABLE 196: Trinity Biotech: Company Profile
TABLE 197: ARKRAY: Company Profile
TABLE 198: LifeScan: Company Profile
TABLE 199: Ascensia Diabetes Care: Company Profile
TABLE 200: Healgen Scientific: Company Profile
TABLE 201: Access Bio: Company Profile
TABLE 202: GenBody America: Company Profile
TABLE 203: bioLytical Laboratories: Company Profile
TABLE 204: Binx Health: Company Profile
TABLE 205: Visby Medical: Company Profile
TABLE 206: Cardinal Health: Company Profile
TABLE 207: PTS Diagnostics: Company Profile
TABLE 208: U.S. Single-Use Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 209: U.S. Single-Use Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 210: U.S. Single-Use Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 211: U.S. Single-Use Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 212: U.S. Single-Use Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 213: U.S. Single-Use Point-of-Care Testing Devices Market: Technology Attractiveness Matrix
TABLE 214: U.S. Single-Use Point-of-Care Testing Devices Market: Application Opportunity Matrix
TABLE 215: U.S. Single-Use Point-of-Care Testing Devices Market: End-Use Expansion Opportunity Analysis
TABLE 216: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Diagnostic Device Manufacturers
TABLE 217: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 218: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Urgent-Care and Physician Networks
TABLE 219: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Retail Pharmacy and Consumer Health Companies
TABLE 220: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 221: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 222: U.S. Single-Use Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 223: U.S. Single-Use Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 224: U.S. Single-Use Point-of-Care Testing Devices Market: Regulatory and CLIA-Waiver Strategy
TABLE 225: U.S. Single-Use Point-of-Care Testing Devices Market: Analyzer Placement and Cartridge Pull-Through Strategy
TABLE 226: U.S. Single-Use Point-of-Care Testing Devices Market: Product Positioning and Assay Menu Expansion Guidance
TABLE 227: U.S. Single-Use Point-of-Care Testing Devices Market: U.S. Geographic Expansion Priorities
TABLE 228: U.S. Single-Use Point-of-Care Testing Devices Market: Partnership, Licensing and M&A Considerations
TABLE 229: U.S. Single-Use Point-of-Care Testing Devices Market: Scope Limitation
TABLE 230: U.S. Single-Use Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 231: U.S. Single-Use Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 232: U.S. Single-Use Point-of-Care Testing Devices Market: Market Definition and Revenue Attribution Limitation
TABLE 233: U.S. Single-Use Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 234: U.S. Single-Use Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Single-Use Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem Framework
FIGURE 4: Stakeholder Ecosystem
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Single-Use Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Single-Use Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Single-Use Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Cost-Per-Result Economics Framework
FIGURE 13: Analyzer Placement and Consumables Pull-Through Model
FIGURE 14: Decentralized Testing Adoption Framework
FIGURE 15: CLIA-Waived Testing Opportunity Map
FIGURE 16: PESTEL Analysis
FIGURE 17: Porter’s Five Forces Analysis
FIGURE 18: Value Chain Analysis
FIGURE 19: Supply Chain Analysis
FIGURE 20: FDA, CLIA and Reimbursement Framework
FIGURE 21: Single-Use Diagnostic Sustainability Framework
FIGURE 22: Product Format Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Product Format Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Test Strips and Dipsticks Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 25: Disposable Test Cassettes and Cards Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Single-Use Reagent and Molecular Cartridges Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Microfluidic and Lab-on-Chip Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 28: Integrated Collection-and-Test Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 29: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Infectious Disease Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Diabetes and Metabolic Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Cardiac and Coagulation Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Pregnancy, Fertility and Women’s Health Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Blood Gas, Electrolyte, Renal and Other Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: Multiplex Respiratory Testing Growth Opportunity, 2025–2035
FIGURE 37: Sample Type Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Sample Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Blood and Capillary Blood Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Nasal and Nasopharyngeal Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Urine Sample Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: Saliva and Oral Fluid Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 43: Other Specimen Types Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 44: End-Use Setting Segment Market Share Analysis, 2025 & 2035
FIGURE 45: End-Use Setting Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Hospitals and Emergency Departments Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Urgent-Care Centers and Physician Offices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Home and Self-Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 49: Retail Pharmacies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 50: Ambulatory, Community and Public-Health Settings Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 51: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 52: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 53: Lateral-Flow Immunoassays Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 54: Electrochemical Biosensors Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 55: Rapid Molecular Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 56: Microfluidic Immunochemistry and Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 57: Optical, Colorimetric and Other Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 58: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 59: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: West Region U.S. Single-Use Point-of-Care Testing Devices Market Share and Growth Outlook, 2025
FIGURE 61: West Region Market Share Analysis by State, 2025
FIGURE 62: West Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 63: California Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 64: Washington Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 65: Arizona Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 66: Colorado Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 67: Oregon Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 68: Utah Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 69: Nevada Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 70: New Mexico Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 71: Idaho Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 72: Montana Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 73: Wyoming Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 74: Alaska Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 75: Hawaii Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 76: Northeast Region U.S. Single-Use Point-of-Care Testing Devices Market Share and Growth Outlook, 2025
FIGURE 77: Northeast Region Market Share Analysis by State, 2025
FIGURE 78: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 79: New York Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 80: Massachusetts Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 81: New Jersey Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 82: Pennsylvania Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 83: Connecticut Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 84: Maine Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 85: Vermont Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 86: New Hampshire Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 87: Rhode Island Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 88: South Region U.S. Single-Use Point-of-Care Testing Devices Market Share and Growth Outlook, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 91: Texas Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 92: Florida Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 93: Georgia Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 94: North Carolina Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 95: Tennessee Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 96: South Carolina Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 97: Alabama Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 98: Mississippi Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 99: Louisiana Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 100: Arkansas Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 101: Kentucky Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 102: Oklahoma Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 103: Virginia Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 104: Maryland Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 105: West Virginia Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 106: Delaware Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 107: Midwest Region U.S. Single-Use Point-of-Care Testing Devices Market Share and Growth Outlook, 2025
FIGURE 108: Midwest Region Market Share Analysis by State, 2025
FIGURE 109: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 110: Illinois Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 111: Ohio Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 112: Michigan Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 113: Minnesota Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 114: Indiana Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 115: Wisconsin Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 116: Missouri Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 117: Iowa Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 118: Kansas Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 119: Nebraska Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 120: North Dakota Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 121: South Dakota Single-Use Point-of-Care Testing Devices Market Size and Forecast, 2021–2035
FIGURE 122: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 123: Company Positioning Matrix
FIGURE 124: Key Player Product Portfolio Benchmarking
FIGURE 125: Analyzer Installed Base and Consumables Pull-Through Benchmarking
FIGURE 126: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 127: Single-Use Point-of-Care Testing Innovation Roadmap
FIGURE 128: Multiplex Rapid Molecular Diagnostics Adoption Roadmap
FIGURE 129: Microfluidic and Lab-on-Chip Technology Opportunity Map
FIGURE 130: Home and OTC Testing Growth Roadmap
FIGURE 131: Connected Point-of-Care Testing Ecosystem
FIGURE 132: Future Market Scenario Analysis, 2026–2035
FIGURE 133: Disruptive Technologies Impact Matrix
FIGURE 134: Emerging Business Trends Matrix
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Technology Attractiveness Matrix
FIGURE 137: Application Opportunity Matrix
FIGURE 138: Strategic Growth Roadmap for U.S. Single-Use POC Testing Companies
FIGURE 139: Go-to-Market Strategy Framework
FIGURE 140: Regulatory and CLIA-Waiver Strategy Framework
FIGURE 141: Analyzer Placement and Cartridge Pull-Through Strategy Framework
FIGURE 142: Product Positioning and Assay Menu Expansion Framework
FIGURE 143: U.S. Geographic Expansion Priority Map
FIGURE 144: Partnership, Licensing and M&A Strategy Framework
FIGURE 145: Report Scope and Disclaimer Framework